Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Change in Acquisitions & Divestments (2025)

NewAmsterdam Pharma's Change in Acquisitions & Divestments history spans 1 years, with the latest figure at $50.5 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments changed N/A year-over-year to $50.5 million; the TTM value through Dec 2025 reached $122.1 million, changed N/A, while the annual FY2025 figure was $122.1 million, N/A changed from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $50.5 million at NewAmsterdam Pharma, up from $34.4 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $50.5 million in Q4 2025 and bottomed at $12.5 million in Q1 2025.